Filing Flows › Beam Therapeutics (BEAM) › R&D spending
Beam Therapeutics (BEAM) R&D spending by quarter
Beam Therapeutics' R&D spending was $110M in Q3 2026 (third quarter 2026), +16% from Q2 2026. Over the last 7 quarters it ranged from $95.1M (Q2 2026) to $110M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $110M | +16% | +0.3% |
| Q2 2026 | $95.1M | -9% | -7% |
| Q1 2026 | $105M | +5% | +6% |
| Q4 2025 | $99.3M | -10% | — |
| Q3 2025 | $110M | +8% | — |
| Q2 2025 | $102M | +3% | — |
| Q1 2025 | $98.8M | — | — |
Q3 2026 at a glance
Beam Therapeutics, Q3 2026: revenue $307K (-97% year over year), net loss $134M, operating cash flow −$111M. The chart follows the revenue to costs, profit and cash.
Questions
What is Beam Therapeutics' R&D spending?
Beam Therapeutics' R&D spending was $110M in Q3 2026 (third quarter 2026), +16% from Q2 2026.
How has Beam Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $95.1M (Q2 2026) to $110M (Q3 2026).